title: Central neurotoxicity of immunomodulatory drugs in multiple myeloma.
abstract: Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Urmeel H
authors: UH
authors: Patel
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Muhammad A
authors: MA
authors: Mir
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Jeffrey K
authors: JK
authors: Sivik
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Divisha
authors: D
authors: Raheja
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Manoj K
authors: MK
authors: Pandey
authors: Penn State Hershey Cancer Institute , Hershey, PA, USA.
authors: Giampaolo
authors: G
authors: Talamo
keywords: central neurotoxicity; immunomodulatory drugs; lenalidomide; multiple myeloma; pomalidomide; thalidomide